Takeshi Omori

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Li‐Tzong Chen, Min‐Hee Ryu et al. · The Lancet Oncology · 2022 · 768 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Serologic evidence for etiologic role of Akabane virus in epizootic abortion-arthrogryposis-hydranencephaly in cattle in Japan, 1972?1974

H. Kurogi, Yuji Inaba, Yuhei Goto et al. · Archives of Virology · 1975 · 141 citations

Veterinary Medicine, Infectious Diseases, Pathobiology +17

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Ronan J. Kelly, Jeeyun Lee, Yung‐Jue Bang et al. · Clinical Cancer Research · 2019 · 129 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients

Masaaki Motoori, Masahiko Yano, Hiroshi Miyata et al. · Clinical Nutrition · 2015 · 127 citations

Medicine, Oncology, Chemotherapy +8

LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study

Narikazu Boku, M.-H. Ryu, D-Y. Oh et al. · Annals of Oncology · 2020 · 124 citations

Medicine, Oncology, Pharmacotherapy +15